Phase II trial of PSA-IL2-GM-CSF-vaccine in patients with prostate cancer

Trial Profile

Phase II trial of PSA-IL2-GM-CSF-vaccine in patients with prostate cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs PSA-IL2-GM-CSF vaccine (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jul 2017 According to an OncBioMune Pharmaceuticals media release, the protocol is awaiting approval from the Institutional Review Board (IRB) at the host hospital, a preeminent North-eastern U.S. cancer research network. The protocol was previously submitted to the U.S. Food and Drug Administration and received no comments within the 30-day comment period.
    • 20 Jun 2017 According to an OncBioMune Pharmaceuticals media release, this study is expected to begin in 2017.
    • 01 Jun 2017 According to an OncBioMune Pharmaceuticals media release, the trial protocol has been submitted to the U.S. Food and Drug Administration (FDA) for review. The investigators are Dr. Rupal Bhatt, Dr. Glenn Bubley and Dr. David Einstein at Beth Israel Deaconess Medical Center of Harvard Medical School.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top